Tailored therapeutic release from polycaprolactone-silica hybrids for the treatment of osteomyelitis: antibiotic rifampicin and osteogenic silicates.

Animals Anti-Bacterial Agents / pharmacology Escherichia coli Osteomyelitis / drug therapy Polyesters Rats Rifampin / pharmacology Silicates / pharmacology Silicon Dioxide / pharmacology Staphylococcal Infections Staphylococcus aureus

Journal

Biomaterials science
ISSN: 2047-4849
Titre abrégé: Biomater Sci
Pays: England
ID NLM: 101593571

Informations de publication

Date de publication:
12 Apr 2022
Historique:
pubmed: 9 3 2022
medline: 15 4 2022
entrez: 8 3 2022
Statut: epublish

Résumé

The treatment of osteomyelitis, a destructive inflammatory process caused by bacterial infections to bone tissue, is one of the most critical challenges of orthopedics and bone regenerative medicine. The standard treatment consists of intense antibiotic therapies combined with tissue surgical debridement and the application of a bone defect filler material. Unfortunately, commercially available candidates, such as gentamicin-impregnated polymethylmethacrylate cements, possess very poor pharmacokinetics (

Identifiants

DOI: 10.1039/d1bm02015c PMID: 35258044
pubmed: 35258044
doi: 10.1039/d1bm02015c
doi:

Substances chimiques

Anti-Bacterial Agents 0
Polyesters 0
Silicates 0
polycaprolactone 24980-41-4
Silicon Dioxide 7631-86-9
Rifampin VJT6J7R4TR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1936-1951

Auteurs

Lukas Gritsch (L)

Laboratoire de Physique de Clermont, UMR CNRS 6533, Université Clermont Auvergne, 4 avenue Blaise Pascal, 63178 Aubière, France. lukas.gritsch@clermont.in2p3.fr.
ORCID: 0000-0002-4483-5064

Henri Granel (H)

Unité de Nutrition Humaine UMR 1019 INRAE, Université Clermont Auvergne, 28 place Henri-Dunant, 63001 Clermont-Ferrand, France.

Nicolas Charbonnel (N)

Université Clermont Auvergne, CNRS, LMGE, 63000 Clermont-Ferrand, France.

Edouard Jallot (E)

Laboratoire de Physique de Clermont, UMR CNRS 6533, Université Clermont Auvergne, 4 avenue Blaise Pascal, 63178 Aubière, France. lukas.gritsch@clermont.in2p3.fr.

Yohann Wittrant (Y)

Unité de Nutrition Humaine UMR 1019 INRAE, Université Clermont Auvergne, 28 place Henri-Dunant, 63001 Clermont-Ferrand, France.
ORCID: 0000-0003-3811-8859

Christiane Forestier (C)

Université Clermont Auvergne, CNRS, LMGE, 63000 Clermont-Ferrand, France.

Jonathan Lao (J)

Laboratoire de Physique de Clermont, UMR CNRS 6533, Université Clermont Auvergne, 4 avenue Blaise Pascal, 63178 Aubière, France. lukas.gritsch@clermont.in2p3.fr.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Tailored therapeutic release from...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Tailored therapeutic release from...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › Tailored therapeutic release from...
questionsmedicales.fr › Maladies ostéomusculaires › Maladies osseuses › Infections osseuses › Ostéomyélite › Tailored therapeutic release from...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyesters › Tailored therapeutic release from...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Tailored therapeutic release from...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › Tailored therapeutic release from...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du silicium › Silice › Acide silicique › Silicates › Tailored therapeutic release from...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du silicium › Silice › Tailored therapeutic release from...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à staphylocoques › Tailored therapeutic release from...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Tailored therapeutic release from...